Christopher Porter, MD

Recognitions

• Paul Calabresi Award in Clinical/Translational Oncology Research, University of Colorado Cancer Center/NCI (2008)
  
• Alpha Omega Alpha Honor Medical Society, Alpha of Georgia Chapter, Medical College of Georgia (1998)
  

Research Interests

Publications

• Casás-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA Jr, Chan DC, Tan AC, DeGregori J. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012 Aug 15;72(16):4154-64. PubMed PMID: 22738915
• Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, Eckhardt SG, Tan AC, DeGregori J, Espinosa JM. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat Chem Biol. 2012 Jul;8(7):646-54. PubMed PMID: 22660439
• Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D, Zaberezhnyy V, Patel PR, Gao D, Tan AC, DeGregori J. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia. 2012 Jun;26(6):1266-76. PubMed PMID: 22289989
• Gore L, DeGregori J, Porter CC. Targeting developmental pathways in children with cancer: what price success? Lancet Oncol. 2013 Feb;14(2):e70-8. PubMed PMID: 23369685
• Choudhary R, Baturin D, Fosmire S, Freed B, Porter CC. Knockdown of HPRT for selection of genetically modified human hematopoietic progenitor cells. PLoS One, 2013, 8(3):e59594.
• Porter CC, Fosmire, S, Tan AC, Gregory M, DeGregori J. Synthetic lethality screening for the development of rational combination therapy for leukemia. Annals of Oncology 23 (S1): i21, 2012.
• Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther. 2013 Dec;12(12):2675-84. PubMed PMID: 24121103
• Choudhary R, Baturin D, Fosmire S, Freed B, Porter CC. Knockdown of HPRT for selection of genetically modified human hematopoietic progenitor cells. PLoS One. 2013;8(3):e59594. PubMed PMID: 23555045
• Gore L, DeGregori J, Porter CC. Targeting developmental pathways in children with cancer: what price success?. Lancet Oncol. 2013 Feb;14(2):e70-8. PubMed PMID: 23369685
• Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP, Hansen RJ, Morgan MJ, Porter CC, Gustafson DL, Thorburn A. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res. 2014 Mar 3. [Epub ahead of print] PubMed PMID: 24590058
• Ford J, Baturin A, Van Linden A, Fosmire S, Porter CC. Wee 1 as a therapeutic target in acute leukemia. Pediatric Blood and Cancer 60 (S2): S39.
• Jones CL, Gearheart CM, Fosmire S, Wang J, Bitterman DS, Bhatla T, Bourgeois, Porter CC, Carroll WL. Genome-Wide shRNA Screen Implicates Mitogen Activated Protein Kinase (MAPK) Pathway in Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.
• Ford J, Baturin A, Van Linden A, Fosmire S, Porter CC. Inhibition of Wee1 enhances the anti-leukemic effects of antimetabolites in vitro and in vivo. Blood (ASH Annual Abstracts) 122 (21), 2013.
• Ford JB, Baturin D, Burleson TM, Van Linden AA, Kim YM, Porter CC. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Oncotarget. 2015 Sep 29;6(29):28001-10. PubMed PMID: 26334102
• Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood. 2015 Aug 31. [Epub ahead of print] PubMed PMID: 26324703
• Ford JB, Baturin D, Burleson TM, Van Linden AA, Kim YM, Porter CC, AZD-1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair.
• Noetzli L, Lee Sherrick A, Callaghan M, Rajpurkar M, Jones K, Gowan K, Savoia A, Hunger SP, Heller P, Guitierrez-Hartman A, Liang X, Pluthero F, Rowley J, Weyrich A, Balduini C, Kahr W†, Porter CC† and Di Paola J†. Germline mutations in ETV6 are associated with thrombocytopenia, macrocytosis and predisposition to lymphoblastic leukemia.
• Ellison MA, Thurman G, Gearheart CM, Seewald RH, Porter CC, Ambruso DR. INF-? Enhances Nox2 Activity by Upregulating phox Proteins When Applied to Differentiating PLB-985 Cells but Does Not Induce Nox2 Activity by Itself. PLoS One. 2015;10(8):e0136766. PubMed PMID: 26317224
• Kirkpatrick G, Noetzli L, Di Paola J, Porter CC. ETV6 mutations define a new cancer predisposition syndrome. Oncotarget. 2015 Jul 10;6(19):16830-1. PubMed PMID: 26219557
• Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savoia A, Rajpurkar M, Jones K, Gowan K, Balduini CL, Pecci A, Gnan C, De Rocco D, Doubek M, Li L, Lu L, Leung R, Landolt-Marticorena C, Hunger S, Heller P, Gutierrez-Hartmann A, Xiayuan L, Pluthero FG, Rowley JW, Weyrich AS, Kahr WH, Porter CC, Di Paola J. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015 May;47(5):535-8. PubMed PMID: 25807284
• Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR. Functional genomic screening identifies the phosphatase PRL-3 as a driver of triple-negative breast cancer and a target of the novel agent AMPI-109.
• Gardner LA, Klawitter J, Gregory MA, Zaberezhnyy V, Baturin D, Pollyea DA, Takebe N, Christians U, Gore L, DeGregori J, Porter CC. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1( ) leukemia. Am J Hematol. 2014 Sep;89(9):896-903. PubMed PMID: 24891015
• Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP, Hansen RJ, Morgan MJ, Porter CC, Gustafson DL, Thorburn A. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res. 2014 May 1;74(9):2579-90. PubMed PMID: 24590058
• Gari HH, Ray R, Lucia S, Porter CC, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Ru Y, Thor AD, Lambert JR. PTP4A3 is oncogenic and modulates triple negative breast cancer growth. Selected for Poster Presentation, American Association for Cancer Research Annual Meeting, April 2014.
• Snedeker J, Burleson T, Tibes R, Porter CC. Combined inhibition of Wee1 and PARP1/2 synergisticaly inhibits AML cells by enhancing DNA damage and the induction of apoptosis. Selected for Poster Presentation - American Society of Hematology Annual Meeting, December 2014. Mr. Snedeker was awarded an ASH Abstract Achievement Award for this submission.
• Jones CL, Gearheart CM, Fosmire S, Delgado-Martin, C, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Raetz EA, Hermiston ML, Garabedian MJ, Porter CC, Carroll WL. MAPK signaling cascades mediate distinct prednisolone resistance mechanisms in pediatric pre-B ALL. Selected for Oral Presentation - American Society of Hematology Annual Meeting, December 2014. Dr. Jones was awarded an ASH Abstract Achievement Award for this submission.

Professional Memberships

• American Society of Hematology, Member
• American Society of Pediatric Hematology Oncology, Member
• American Association for Cancer Research, Member
• American Academy of Pediatrics (AAP), Fellow
• Children's Oncology Group, Member
• American Society of Gene Therapy, Member
• University of Colorado Cancer Center, Member
• Colorado Multiple Institutional Review Board, Panel C (Pediatrics), Member
• University of Colorado Cancer Center Protocol Review & Monitoring Committee, Member

Practice Locations

• University of Colorado Cancer Center
• Colorado Clinical & Translational Sciences Institute (CCTSI)

Specialty Information

• Pediatrics, Board Certification (2002)
• Pediatric Hematology / Oncology, Board Certification (2007)

• Blood / Lymphatic System - Blood Disorders
• Cancers - Leukemia (Childhood)
• Cancers - Pediatric Cancer
• Cancers - Leukemia (Adult Chronic)
• Blood / Lymphatic System
• Cancers